News

In a 21-patient cohort of celiac disease sufferers, the oral administration of AT1001 induced a significantly positive result in the trial’s primary target endpoint compared to placebo. “We

The problem of medication non-adherence adds an estimated $100 billion to healthcare spending in the US every year, according to a study from The New England Journal of

The findings, presented at the 55th annual scientific session of the American College of Cardiology, mark the first time that a statin has demonstrated a regression in artery

The study enrolled 391 patients, who were assessed after six months of therapy. Results from the study showed NM-702 was associated with a statistically significant increase in patients’

In a phase I randomized, double-blind trial of 18 healthy volunteers, results showed that, in the treated subjects, ozone-induced sputum neutrophilia was inhibited. Neutrophils are believed to play

Under the terms of the agreement, Watson will acquire all of the outstanding shares of Andrx common stock for a cash amount of $25 per share. The boards

The phase IIb data, which indicate that therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia (CLI), were released in a late-breaking clinical

The analysis showed that Vytorin (ezetimibe/simvastatin) reduced LDL cholesterol by an average of 52.5% and C-reactive protein (CRP) by an average of 31%, compared to averages of 38%

The results from the 553-patient phase III peripheral arterial disease (PAD) trial, named SIMPADICO, showed that the study did not reach the primary endpoint of change in maximal